Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors-United States, July 2016-June 2019
Published by Oxford University Press for the Infectious Diseases Society of America 2021..
We analyzed administrative data to determine the 1-year incidence of invasive fungal infections (IFIs) in patients beginning small molecule kinase inhibitor (SMKI) therapy. The incidence of IFIs by small molecule kinase inhibitor ranged from 0.0% to 10.6%, with patients taking midostaurin having the highest incidence. An IFI developed in 38 of 1286 patients taking ibrutinib (3.0%).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 75(2022), 2 vom: 25. Aug., Seite 334-337 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gold, Jeremy A W [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1X70OSD4VX |
|---|
| Anmerkungen: |
Date Completed 29.08.2022 Date Revised 23.11.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciab1026 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334303214 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334303214 | ||
| 003 | DE-627 | ||
| 005 | 20231225223425.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciab1026 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1114.xml |
| 035 | |a (DE-627)NLM334303214 | ||
| 035 | |a (NLM)34893821 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gold, Jeremy A W |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors-United States, July 2016-June 2019 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.08.2022 | ||
| 500 | |a Date Revised 23.11.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Published by Oxford University Press for the Infectious Diseases Society of America 2021. | ||
| 520 | |a We analyzed administrative data to determine the 1-year incidence of invasive fungal infections (IFIs) in patients beginning small molecule kinase inhibitor (SMKI) therapy. The incidence of IFIs by small molecule kinase inhibitor ranged from 0.0% to 10.6%, with patients taking midostaurin having the highest incidence. An IFI developed in 38 of 1286 patients taking ibrutinib (3.0%) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a ibrutinib | |
| 650 | 4 | |a invasive fungal infections | |
| 650 | 4 | |a opportunistic infections | |
| 650 | 4 | |a small molecule kinase inhibitors | |
| 650 | 7 | |a Piperidines |2 NLM | |
| 650 | 7 | |a ibrutinib |2 NLM | |
| 650 | 7 | |a 1X70OSD4VX |2 NLM | |
| 650 | 7 | |a Adenine |2 NLM | |
| 650 | 7 | |a JAC85A2161 |2 NLM | |
| 700 | 1 | |a Tolu, Seda S |e verfasserin |4 aut | |
| 700 | 1 | |a Chiller, Tom |e verfasserin |4 aut | |
| 700 | 1 | |a Benedict, Kaitlin |e verfasserin |4 aut | |
| 700 | 1 | |a Jackson, Brendan R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 75(2022), 2 vom: 25. Aug., Seite 334-337 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2022 |g number:2 |g day:25 |g month:08 |g pages:334-337 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciab1026 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2022 |e 2 |b 25 |c 08 |h 334-337 | ||